Anti-Endothelial Cell Antibodies in Patients with Alzheimer Disease (P05.052)

Abstract

Objective: To examine the presence of antiendothelial cell antibodies (AECAs) specific for Alzheimer disease (AD), and to evaluate the association of these antibodies with cognitive impairment. Background Previous studies have reported that the BBB impairment may be a pathogenetic mechanism contributing to cognitive impairment in AD. However, the mechanism of BBB impairment in AD is unknown. We hypothesized that AECA associated with BBB impairment is present in AD. Design/Methods: The study included AD patients (aged ≥ 60 years; 24 patients), control subjects without neurologic diseases (aged ≥ 60 years; 19 subjects), healthy control subjects (aged Results: We detected 5 spots that reacted with AECAs, which frequently appeared in sera from AD patients. These 5 immunoreactive spots were identified as Vimentin; Protein disulfide-isomerase A3; Alpha enolase; Mitochondrial import receptor subunit TOM40 homolog (Tom40); and Annexin A2. The anti-Tom40 antibody was identified significantly more frequently in AD patients than it was in control subjects or patients with multiple sclerosis. In AD patients, the mean scores for the mini-mental state examination were significantly lower for patients who were positive for the anti-Tom40 antibody than they were for those patients who were negative for the anti-Tom40 antibody. Conclusions: The anti-Tom40 antibody is significantly associated with cognitive impairment in AD patients. Disclosure: Dr. Kimura has nothing to disclose. Dr. Sakurai has nothing to disclose. Dr. Yamada has nothing to disclose. Dr. Koumura has nothing to disclose. Dr. Hayashi has nothing to disclose. Dr. Tanaka has nothing to disclose. Dr. Hozumi has nothing to disclose. Dr. Otaki has nothing to disclose. Dr. Chousa has nothing to disclose. Dr. Inuzuka has nothing to disclose.